FDA to Commit to Faster End-of-Phase Meetings in Guidance to Developers

Drug Industry Daily
A A
FDA released two guidance documents focusing on communications between the agency and drug developers to make drug development more efficient and to help sponsors avoid costly delays.

To View This Article:

Login

Subscribe To Drug Industry Daily